Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out

With new Phase I/Ib results in kidney cancer, the HIF-2a inhibitor outshines Merck’s Welireg, but longtime Arcus partner Gilead decided not to exercise its option for casdatifan.